» Articles » PMID: 35511762

Predictive Models in SMA II Natural History Trajectories Using Machine Learning: A Proof of Concept Study

Abstract

It is known from previous literature that type II Spinal Muscular Atrophy (SMA) patients generally, after the age of 5 years, presents a steep deterioration until puberty followed by a relative stability, as most abilities have been lost. Although it is possible to identify points of slope indicating early improvement, steep decline and relative stabilizations, there is still a lot of variability within each age group and it's not always possible to predict individual trajectories of progression from age only. The aim of the study was to develop a predictive model based on machine learning using an XGBoost algorithm for regression and report, explore and quantify, in a single centre longitudinal natural history study, the influence of clinical variables on the 6/12-months Hammersmith Motor Functional Scale Expanded score prediction (HFMSE). This study represents the first approach to artificial intelligence and trained models for the prediction of individualized trajectories of HFMSE disease progression using individual characteristics of the patient. The application of this method to larger cohorts may allow to identify different classes of progression, a crucial information at the time of the new commercially available therapies.

Citing Articles

Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.

Coratti G, Bovis F, Pera M, Scoto M, Montes J, Pasternak A Eur J Neurol. 2024; 31(8):e16309.

PMID: 38656662 PMC: 11236020. DOI: 10.1111/ene.16309.


New therapies for spinal muscular atrophy: where we stand and what is next.

Antonaci L, Pera M, Mercuri E Eur J Pediatr. 2023; 182(7):2935-2942.

PMID: 37067602 PMC: 10354145. DOI: 10.1007/s00431-023-04883-8.

References
1.
Mercuri E, Finkel R, Montes J, Mazzone E, Sormani M, Main M . Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscul Disord. 2016; 26(2):126-31. PMC: 4762230. DOI: 10.1016/j.nmd.2015.10.006. View

2.
Coratti G, Pera M, Lucibello S, Montes J, Pasternak A, Mayhew A . Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord. 2020; 30(9):756-764. DOI: 10.1016/j.nmd.2020.07.005. View

3.
Vazquez-Costa J, Povedano M, Nascimiento-Osorio A, Moreno Escribano A, Garcia S, Dominguez R . Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2022; 29(12):3666-3675. PMC: 9826246. DOI: 10.1111/ene.15542. View

4.
Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J . Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. PLoS One. 2016; 11(10):e0164684. PMC: 5063281. DOI: 10.1371/journal.pone.0164684. View

5.
Pera M, Coratti G, Mazzone E, Montes J, Scoto M, de Sanctis R . Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019; 59(4):426-430. DOI: 10.1002/mus.26419. View